Kinarus Therapeutics Holding AG
SIX:KNRS

Watchlist Manager
Kinarus Therapeutics Holding AG Logo
Kinarus Therapeutics Holding AG
SIX:KNRS
Watchlist
Price: 15 CHF 416 566.67%
Market Cap: 19.5B CHF

Net Margin
Kinarus Therapeutics Holding AG

0%
Current
0.1%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.9m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Kinarus Therapeutics Holding AG
Glance View

Market Cap
19.5B CHF
Industry
Airlines

Kinarus Therapeutics Holding AG, a biopharmaceutical company based in Switzerland, emerges at the crossroads of innovative science and unmet medical needs. The company is committed to pioneering novel therapies for chronic disorders, with a strong focus on ophthalmology and fibrotic diseases. At the heart of its operations lies an unwavering dedication to developing pharmaceuticals that can significantly improve patients' lives. Kinarus employs a distinctive approach by repurposing existing drugs, thereby accelerating the development process and reducing the inherent risks associated with new drug development. This strategy allows the firm to quickly advance its candidates through clinical trials, capitalizing on existing safety profiles while innovating in therapeutic efficacy. The company's financial engine runs on a clinical-stage pipeline that harnesses the potential of drug candidates designed to tackle chronic and progressive conditions. Kinarus generates revenue primarily by advancing these candidates through different phases of clinical trials, aiming for favorable outcomes that will attract partnerships with larger pharmaceutical entities or lead to potential out-licensing agreements. As these collaborations materialize, Kinarus can secure milestone payments, royalties, and licensing fees, which feed back into its research and development endeavors. By striking a balance between scientific acumen and strategic partnerships, Kinarus Therapeutics continues to forge pathways in the biopharmaceutical sector, seeking not only to create financial value but also to deliver transformative solutions for enduring health challenges.

KNRS Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.9m
/
Revenue
0
What is the Net Margin of Kinarus Therapeutics Holding AG?

Based on Kinarus Therapeutics Holding AG's most recent financial statements, the company has Net Margin of 0%.

Back to Top